Drug Pipeline & Clinical Update - October 2026

Highlights
- 2 key new drug approvals, including Hovilpri (pritelivir) oral tablet
- 6 notable expanded indications, including Ryzumvi® (phentolamine) – expanded to treat presbyopia in adults
- 1 Generic Launch: Adempas® (Riociguat) oral tablet
- Judi Rx's updated drug recall report: CLICK HERE to review.
Judi Health closely monitors the drug landscape to provide our clients with timely information on newly FDA approved medications and products in the pipeline. Please find the October 2026 Monthly Drug Update below:
Key New Drug Approvals
Hovilpri (pritelivir) oral tablet
Approval Date: 10/09/2026
Indication: Treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacyclovir, or famciclovir
Cost*: TBD
Key Consideration:
- Recommended dose is 400 mg (4 tablets) on the day one, followed by 100 mg (1 tablet) once daily with or without food, until lesions have healed
- Received priority review by the FDA
Press Release: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-lesions-caused-herpes-simplex-virus
Hibsago (bepirovirsen) subcutaneous injection
Approval Date: 10/20/2026
Indication: Treatment of chronic HBV infection in adult patients without cirrhosis, in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy
Cost*: TBD
Key Consideration:
- Black box warning for hepatic flares and thrombocytopenia
- Received priority review by the FDA
Press Release: https://us.gsk.com/en-us/media/press-releases/hibsago-bepirovirsen-approved-in-the-us-for-the-treatment-of-chronic-hepatitis-b-chb/
Notable Expanded Indications
- Jaypirca® (pirtobrutinib) – expanded to treat adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion
- Rhapsido® (remibrutinib) – expanded to treat symptomatic dermographism
- Tukysa® (tucatinib) – expanded to treat adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting, in combination with trastuzumab and capecitabine
- Velphoro® (sucroferric oxyhydroxide) – expanded to control serum phosphorus levels in patients 6 years of age and older with chronic kidney disease on dialysis
- Ryzumvi® (phentolamine) – expanded to treat presbyopia in adults
- Talzenna® (talazoparib) – expanded to treat metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations, as detected by an FDA authorized test
Generic Launches
- Adempas® (Riociguat) oral tablet
*Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support
.webp)





